The global market for hemostasis testing systems is undergoing a dynamic transformation, fueled by technological innovation, increasing prevalence of bleeding and thrombotic disorders, and an ...

Chronic DIC is defined as a state of intravascular coagulation, and only minor imbalances in hemostasis exist. Acute DIC can also be seen in cancer patients and is an escape of the normal ...

A combination of pharmacologic and endoscopic therapy (using a combination of injection and thermal coagulation) offers the best chance of hemostasis for those with active bleeding ulcers.

The global blood coagulation analyzers market is on a robust growth trajectory, projected to expand from USD 3,038.9 million in 2023 to USD 5,680.7 million by 2033, registering a CAGR of 6.5% during ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin generation to restore hemostasis in people with hemophilia. Qfitlia uses small-interfering RNA technology ...

Fitusiran is a subcutaneous prophylactic small interfering RNA therapy, which targets antithrombin to restore thrombin generation and rebalance hemostasis ... events (blood clotting) and ...